MA30868B1 - Derives de 2-aminocarbonyl-pyridine - Google Patents

Derives de 2-aminocarbonyl-pyridine

Info

Publication number
MA30868B1
MA30868B1 MA31845A MA31845A MA30868B1 MA 30868 B1 MA30868 B1 MA 30868B1 MA 31845 A MA31845 A MA 31845A MA 31845 A MA31845 A MA 31845A MA 30868 B1 MA30868 B1 MA 30868B1
Authority
MA
Morocco
Prior art keywords
aminocarbonyl
pyridine derivatives
vascular
viscerovascular
hepato
Prior art date
Application number
MA31845A
Other languages
English (en)
Inventor
Eva Caroff
Kurt Hilpert
Emmanuel Meyer
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39167796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30868(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA30868B1 publication Critical patent/MA30868B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/803Processes of preparation
    • C07D213/807Processes of preparation by oxidation of pyridines or condensed pyridines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

LA PRÉSENTE INVENTION CONCERNE DES DÉRIVÉS DE 2-AMINOCARBONYL-PYRIDINE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE P2YI2 DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES OU D'AFFECTIONS VASCULAIRES PÉRIPHÉRIQUES, VISCÉRO-VASCULAIRES, HÉPATO-VASCULAIRES ET VASCULAIRES RÉNALES, CARDIOVASCULAIRES ET CÉRÉBRO-VASCULAIRES ASSOCIÉES À L'AGRÉGATION DES PLAQUETTES, Y COMPRIS LA THROMBOSE, CHEZ LES HUMAINS ET D'AUTRES MAMMIFÈRES.
MA31845A 2006-10-13 2009-05-06 Derives de 2-aminocarbonyl-pyridine MA30868B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2006053773 2006-10-13
IB2006053817 2006-10-17

Publications (1)

Publication Number Publication Date
MA30868B1 true MA30868B1 (fr) 2009-11-02

Family

ID=39167796

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31845A MA30868B1 (fr) 2006-10-13 2009-05-06 Derives de 2-aminocarbonyl-pyridine

Country Status (17)

Country Link
US (1) US8093250B2 (fr)
EP (1) EP2081903B1 (fr)
JP (1) JP5341763B2 (fr)
KR (1) KR101525260B1 (fr)
AR (1) AR063258A1 (fr)
AU (1) AU2007305925A1 (fr)
BR (1) BRPI0720193A2 (fr)
CA (1) CA2664579C (fr)
CL (1) CL2007002920A1 (fr)
ES (1) ES2473609T3 (fr)
IL (1) IL198059A0 (fr)
MA (1) MA30868B1 (fr)
MX (1) MX2009003724A (fr)
NO (1) NO20091838L (fr)
RU (1) RU2009117705A (fr)
TW (1) TW200823190A (fr)
WO (1) WO2008044217A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
AR063258A1 (es) 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
RU2483072C2 (ru) 2007-11-29 2013-05-27 Актелион Фармасьютиклз Лтд Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
EP2262766B1 (fr) 2008-02-29 2015-11-11 Evotec AG Composés amides, compositions à base de ces composés et leurs utilisations
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
EP2346825A2 (fr) 2008-09-18 2011-07-27 Evotec AG Composés amides, compositions et utilisations des composés et compositions
SG175075A1 (en) 2009-04-08 2011-11-28 Actelion Pharmaceuticals Ltd 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines as adp receptor antagonists
ES2469847T3 (es) 2009-04-22 2014-06-20 Actelion Pharmaceuticals Ltd. Derivados de tiazol y su uso como antagonistas del receptor P2Y12
EP2593434A1 (fr) * 2010-07-16 2013-05-22 Purdue Pharma LP Composés pyridines comme bloqueurs des canaux sodiques
WO2013033178A1 (fr) 2011-08-30 2013-03-07 University Of Utah Research Foundation Procédés et compositions pour traiter le diabète insipide néphrogénique
WO2013136170A1 (fr) 2012-03-16 2013-09-19 Purdue Pharma L.P. Pyridines substituées en tant que bloqueurs des canaux sodiques
EP2935257B1 (fr) 2012-12-20 2018-02-07 Purdue Pharma LP Sulfonamides cycliques en tant que bloquants des canaux sodiques
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
CN109715639B (zh) 2016-09-22 2022-04-19 爱杜西亚药品有限公司 结晶形式
MA49887A (fr) 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (fr) 1989-07-05 1991-01-06 Yoshihide Fuse Derive de cinnamamide
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
WO1999006402A1 (fr) * 1997-07-31 1999-02-11 Ube Industries, Ltd. Composes amides n-acylamino acides et intermediaires utiles dans la preparation de ceux-ci
AU5414000A (en) 1999-06-14 2001-01-02 Eli Lilly And Company Compounds
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
DE60333866D1 (de) * 2002-12-11 2010-09-30 Bayer Schering Pharma Ag 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
TW200640877A (en) * 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
AR057836A1 (es) * 2005-10-21 2007-12-19 Actelion Pharmaceuticals Ltd Piperizinas como agentes contra la malaria
AR063258A1 (es) 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
RU2483072C2 (ru) 2007-11-29 2013-05-27 Актелион Фармасьютиклз Лтд Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
SG175075A1 (en) 2009-04-08 2011-11-28 Actelion Pharmaceuticals Ltd 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines as adp receptor antagonists
ES2469847T3 (es) 2009-04-22 2014-06-20 Actelion Pharmaceuticals Ltd. Derivados de tiazol y su uso como antagonistas del receptor P2Y12

Also Published As

Publication number Publication date
KR20090086075A (ko) 2009-08-10
EP2081903A2 (fr) 2009-07-29
JP5341763B2 (ja) 2013-11-13
CL2007002920A1 (es) 2008-06-06
ES2473609T3 (es) 2014-07-07
MX2009003724A (es) 2009-04-22
CA2664579C (fr) 2014-09-30
WO2008044217A2 (fr) 2008-04-17
US20100035895A1 (en) 2010-02-11
TW200823190A (en) 2008-06-01
WO2008044217A3 (fr) 2008-06-19
RU2009117705A (ru) 2010-11-20
US8093250B2 (en) 2012-01-10
AR063258A1 (es) 2009-01-14
EP2081903B1 (fr) 2014-05-07
AU2007305925A1 (en) 2008-04-17
NO20091838L (no) 2009-05-12
KR101525260B1 (ko) 2015-06-02
JP2010505940A (ja) 2010-02-25
CA2664579A1 (fr) 2008-04-17
BRPI0720193A2 (pt) 2013-12-31
IL198059A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
MA30868B1 (fr) Derives de 2-aminocarbonyl-pyridine
MA30903B1 (fr) Derives de 2 - phenyl-6-minocarbonyl-pyrimidine
MA32277B1 (fr) Derives de 2-phenyl-4- cyclopropyl-pyrimidine
MA31983B1 (fr) Dérivés d'acide phosphonique et leur utilisation en tant qu'antagonistes du récepteur p2y12
MA33277B1 (fr) Dérivés de thiazole et leur utilisation comme antagonistes des récepteurs p2y12
WO2006114774A3 (fr) Derives de pyrimidine
MA33260B1 (fr) 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
MA31920B1 (fr) 4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation
MA31767B1 (fr) Composes organiques et leurs utilisations
MA30900B1 (fr) Anticorps d'agonistes anti-notch3 et leur utilisation dans le traitement de maladies liées à notch3
MA33123B1 (fr) 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation
MA34721B1 (fr) Acides carboxyliques 1-benzylcycloalkyle substitués et leur utilisation
MA28755B1 (fr) Derives de pyrimidine fusionnes et compositions sur leur base, utilises en tant que modulateurs du recepteur de cxcr3, utiles dans la prevention et le traitement de maladies et troubles inflammatoires ou immunoregulateurs
MA30384B1 (fr) Therapies combinatoires
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA32804B1 (fr) Antagonistes d'isonicotinamide des récepteurs de l'orexine
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
MA30041B1 (fr) Immunoglobulines
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
MA29976B1 (fr) Utilisation d'inhibiteurs de la voie du complement pour traiter des maladies oculaires.
MA31245B1 (fr) Amides de 4-aryl-1,4-dihydro-1,6-naphthyridine substitués et utilisation de ceux-ci
MA32282B1 (fr) Dérivés de 2-phényl-pyridine substitués
MA31570B1 (fr) Oxazolidinones substitués et leur utilisation
EA200800667A1 (ru) Аптамеры, связывающие тромбин с высокой аффинностью
MA31535B1 (fr) (oxazolidinon-5-yl-méthyl)-2-thiophène-carboxamides substitués et leur utilisation dans le domaine de la coagulation sanguine